FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2690-2691 June 26, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Rituximab targets CD20+ B cells. It is used increasingly for the treatment of B-cell non-Hodgkin's lymphoma, alone or in combination with cytotoxic agents.^1,2 We report two patients with non-Hodgkin's lymphoma in whom interstitial pneumonitis developed after rituximab therapy.

Patient 1 was an 82-year-old woman who presented with bruising. Her blood count showed a hemoglobin concentration of 8.6 g per deciliter, a white-cell count of 57,100 per cubic millimeter, a lymphocyte count of 44,900 per cubic millimeter, and a platelet count of 32,000 per cubic millimeter. A bone marrow biopsy showed diffuse infiltration with small BCL1+ and CD20+ . . . [Full Text of this Article]

This article has been cited by other articles:

• Nieuwenhuizen, L., Verzijlbergen, F. J., Wiltink, E., Grutters, J. C., Biesma, D. H. (2008). A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma. haematol 93: 1267-1269 [Full Text]  
• Nitta, E, Izutsu, K, Sato, T, Ota, Y, Takeuchi, K, Kamijo, A, Takahashi, K, Oshima, K, Kanda, Y, Chiba, S, Motokura, T, Kurokawa, M (2007). A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18: 364-369 [Abstract] [Full Text]  
• Dimopoulou, I., Bamias, A., Lyberopoulos, P., Dimopoulos, M. A. (2006). Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372-379 [Abstract] [Full Text]  
• Ghesquieres, H. (2005). Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 16: 1399-1399 [Full Text]  
• Edwards, J. C. W., Cambridge, G. (2005). Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44: 151-156 [Full Text]